EU Sounds Alarm On Critical Lithium Shortage
The EU needs 18X more lithium for neutrality in 2030- and this one company may solve the shortage.

NYSE:STE - STERIS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $214.25
  • Forecasted Upside: 2.32 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$209.39
▲ +0.76 (0.36%)
1 month | 3 months | 12 months
Get New STERIS Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$214.25
▲ +2.32% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for STERIS in the last 3 months. The average price target is $214.25, with a high forecast of $230.00 and a low forecast of $200.00. The average price target represents a 2.32% upside from the last price of $209.39.
The #1 Way to Play the CBD Sector
A proprietary product line, unmatched distribution formula, and exponential growth potential in an explosive industry makes this company the top way to play the legal cannabis sector
Buy
The current consensus among 5 investment analysts is to buy stock in STERIS. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/20/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/17/2021KeyCorpBoost Price TargetOverweight$224.00 ➝ $227.00Low
i
3/11/2021KeyCorpBoost Price TargetOverweight$224.00 ➝ $227.00Low
i
2/4/2021KeyCorpUpgradeSector Weight ➝ Overweight$224.00Low
i
1/20/2021Raymond JamesReiterated RatingHoldLow
i
1/13/2021Robert W. BairdBoost Price TargetOutperform$200.00 ➝ $230.00Low
i
11/20/2020Needham & Company LLCReiterated RatingHoldMedium
i
Rating by Michael Matson at Needham & Company LLC
10/8/2020JMP SecuritiesBoost Price Target$180.00 ➝ $200.00Low
i
10/7/2020StephensBoost Price Target$170.00 ➝ $200.00Low
i
10/7/2020Robert W. BairdBoost Price TargetOutperform$175.00 ➝ $200.00Medium
i
10/6/2020Needham & Company LLCReiterated RatingHoldMedium
i
Rating by Michael Matson at Needham & Company LLC
9/1/2020Robert W. BairdInitiated CoverageOutperform$175.00High
i
8/3/2020Needham & Company LLCInitiated CoverageHoldHigh
i
Rating by Michael Matson at Needham & Company LLC
6/9/2020Needham & Company LLCInitiated CoverageHoldMedium
i
5/15/2020StephensBoost Price TargetOverweight$145.00 ➝ $170.00Low
i
3/23/2020StephensLower Price TargetOverweight$177.00 ➝ $145.00High
i
2/12/2020Northcoast ResearchReiterated RatingBuyLow
i
Rating by D. Keiser at Northcoast Research
2/12/2020StephensBoost Price TargetOverweight$165.00 ➝ $177.00High
i
5/22/2019JMP SecuritiesBoost Price TargetMarket Outperform$135.00 ➝ $150.00Low
i
5/15/2019StephensBoost Price TargetOverweight$135.00 ➝ $150.00Low
i
5/15/2019KeyCorpBoost Price TargetOverweight$135.00 ➝ $138.00Low
i
2/14/2019StephensReiterated RatingBuy$135.00Low
i
2/14/2019JMP SecuritiesReiterated RatingBuy$135.00Low
i
12/6/2018SidotiBoost Price TargetBuy ➝ Buy$155.00 ➝ $157.00Low
i
11/13/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$120.00 ➝ $132.00Low
i
8/9/2018JMP SecuritiesBoost Price TargetMarket Outperform ➝ Market Outperform$113.00 ➝ $125.00Low
i
8/9/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$115.00 ➝ $120.00Low
i
8/9/2018StephensReiterated RatingBuy$125.00Low
i
2/8/2018KeyCorpReiterated RatingBuy$103.00Medium
i
2/8/2018Northcoast ResearchSet Price TargetBuy$102.00Medium
i
Rating by David Keiser at Northcoast Research
1/3/2018Raymond JamesReiterated RatingOutperform ➝ Market Perform$100.00High
i
11/9/2017TD SecuritiesBoost Price TargetBuyC$14.00 ➝ C$16.00N/A
i
11/2/2017KeyCorpReiterated RatingOverweight$91.00 ➝ $101.00N/A
i
10/17/2017KeyCorpReiterated RatingBuy$91.00N/A
i
Rating by Matthew Mishan at KeyCorp
10/16/2017Raymond JamesBoost Price TargetOutperform$95.00 ➝ $100.00N/A
i
8/9/2017Raymond JamesBoost Price TargetOutperform$90.00 ➝ $95.00Low
i
6/5/2017Wellington ShieldsDowngradeGradually Accumulate ➝ HoldLow
i
5/3/2017KeyCorpUpgradeSector Weight ➝ Overweight$89.00High
i
11/30/2016The Goldman Sachs GroupInitiated CoverageNeutral$71.00N/A
i
11/4/2016JMP SecuritiesReiterated RatingBuyN/A
i
6/3/2016Northcoast ResearchUpgradeNeutral ➝ BuyN/A
i
Rating by D. Keiser at Northcoast Research
(Data available from 4/21/2016 forward)
STERIS logo
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services. This segment offers its products and services to acute care hospitals, ambulatory surgery centers, and GI clinics. The Healthcare Specialty Services segment provides solutions and managed services, such as instrument and endoscope repair and maintenance solutions; custom process improvement consulting services; and outsourced instrument sterile processing services to acute care hospitals and other healthcare settings. The Life Sciences segment offers formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The company was founded in 1985 and is based in Dublin, Ireland.
Read More

Today's Range

Now: $209.39
$207.94
$211.26

50 Day Range

MA: $190.24
$171.20
$208.63

52 Week Range

Now: $209.39
$138.66
$211.26

Volume

770,420 shs

Average Volume

624,975 shs

Market Capitalization

$17.87 billion

P/E Ratio

42.47

Dividend Yield

0.77%

Beta

0.59

Frequently Asked Questions

What sell-side analysts currently cover shares of STERIS?

The following equities research analysts have issued reports on STERIS in the last year: JMP Securities, KeyCorp, Needham & Company LLC, Raymond James, Robert W. Baird, Stephens, and Zacks Investment Research.
View the latest analyst ratings for STE.

What is the current price target for STERIS?

4 Wall Street analysts have set twelve-month price targets for STERIS in the last year. Their average twelve-month price target is $214.25, suggesting a possible upside of 2.3%. Robert W. Baird has the highest price target set, predicting STE will reach $230.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $200.00 for STERIS in the next year.
View the latest price targets for STE.

What is the current consensus analyst rating for STERIS?

STERIS currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STE will outperform the market and that investors should add to their positions of STERIS.
View the latest ratings for STE.

What other companies compete with STERIS?

How do I contact STERIS's investor relations team?

STERIS's physical mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The medical equipment provider's listed phone number is 353-1232-2000 and its investor relations email address is [email protected] The official website for STERIS is www.steris.com.

AI Healthtech Breakthrough
This stock's cancer detection AI could disrupt the industry. You need to read this report now!